|Bid||41.36 x 900|
|Ask||41.37 x 3200|
|Day's Range||41.28 - 41.71|
|52 Week Range||35.32 - 46.47|
|Beta (3Y Monthly)||0.54|
|PE Ratio (TTM)||21.29|
|Earnings Date||Jul 29, 2019 - Aug 2, 2019|
|Forward Dividend & Yield||1.44 (3.55%)|
|1y Target Est||45.00|
Learn about the forces driving the Chinese economy and helping the country earn money. China has the first or second largest GDP in the world but is not nearly as developed as others in the top 10.
FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
posted gains on Thursday after the drugmaker was named a "top pick" at Credit Suisse following a meeting the analysts had with Pfizer's management team. In a note to clients, Credit Suisse said its meeting with senior Pfizer executives boosted its confidence in both management and the prospects for new products. The move follows Credit Suisse's recent stock-price upgrade on Pfizer, in which analyst Vamil Divan raised his 12-month price target to $48 while maintaining an outperform rating.
The retail giant reported adjusted quarterly profit of $1.13 per share , 11 cents a share above Wall Street forecasts. Cisco Systems CSCO — Cisco reported adjusted quarterly profit of 78 cents per share , beating the consensus estimate of 77 cents a share. The networking equipment maker's revenue also beat Street forecasts, and Cisco also gave better-than-expected current-quarter revenue guidance.
The prices of generic drugs across the universe of pharmaceutical companies appeared to stabilize in the first quarter — shucking off years of broad decline, Wall Street analysts say.
Dow Jones component Pfizer could outperform Wall Street expectations for a newly approved rare heart disease treatment, an analyst said Wednesday as he named Pfizer stock a "top pick."
Pfizer stock has fallen 7.1% this year, behind pharma stocks. Recent news has been upbeat with a drug approval and earnings beat. But the question remains: Is Pfizer stock a buy right now?
Teva Pharmaceutical shares continue to fall amid concerns about a lawsuit over alleged price fixing among generic drugmakers.
Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 14) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc ...
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
Pfizer Inc's new atopic dermatitis treatment met the main goals in a late-stage study that tested the drug in patients aged 12 and older with moderate to severe forms of the disease, the drugmaker said on Wednesday. Abrocitinib, which belongs to a class of drugs known as JAK inhibitors, which block inflammation-causing enzymes, known as Janus kinases, achieved statistically significant improvement in clearing the skin of patients as compared to placebo. The results of the study, which tested two doses of the drug in 387 patients, showed abrocitinib was consistently well-tolerated, Pfizer said.
Formulations of select antivirals will be developed using Matinas’ LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Promising formulations will be tested in in vivo preclinical studies to identify a lead LNC-antiviral formulation to take forward in development.
Pfizer Inc's dermatitis treatment met the main goals in a late-study, testing the drug in patients aged 12 and older with moderate to severe form of the disease, the drugmaker said on Wednesday. The study tested two doses of the drug, abrocitinib, in 387 patients with atopic dermatitis, the company said. Atopic dermatitis is a chronic skin disease characterized by inflammation of the skin and skin barrier defects.
Pfizer Inc. (PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and older with moderate to severe atopic dermatitis (AD).
DARMSTADT, Germany and NEW YORK , May 15, 2019 /PRNewswire/ -- Not intended for US, Canada and UK-based media BAVENCIO is the first anti-PD-L1 in combination with axitinib approved by FDA for first-line ...
Not intended for UK-based media ROCKLAND, Mass. and NEW YORK , May 14, 2019 /PRNewswire/ -- BAVENCIO is the first anti-PD-L1 in combination with INLYTA approved by FDA for first-line treatment of patients ...